OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press68410.17650/1818-8346-2007-0-3-76-80SEMINAR IN HEMATOLOGYCЕМИНАР ПО ГЕМАТОЛОГИИRecombinant erythropoietin in the treatment of anemia in cancer patientsРекомбинантные эритропоэтины в лечении анемии онкологических больныхVorobiovaS. V.ВоробьеваС. В.
Russian Federation

Moscow

Москва

CherniavskayaT. Z.ЧернявскаяТ. З.
Russian Federation

Moscow

Москва

PushkarevaS. G.ПушкареваС. Г.
Russian Federation

Moscow

Москва

FrolovG. P.ФроловГ. П.
Russian Federation

Moscow

Москва

MelkovaK. N.МелковаК. Н.
Russian Federation

Moscow

Москва

N.N. Blokhin Cancer Research CenteГУ РОНЦ им. Н.Н. Блохина РАМНState Research Center –Institute of biophysicsГНЦ Институт биофизики230820073768023112022231120222007https://oncohematology.abvpress.ru/ongm/article/view/684

This article reviews the role of recombinant erythropoietin in the management of anemia in cancer patients based on literature data and our experience. We describe the problem of toxicity and report clinical recommendations and cautions for usage of drugs appertain to this pharmaceutical group.

В статье на основании данных литературы и собственного опыта освещены основные современные представления о роли рекомбинантных эритропоэтинов в лечении анемии онкологических больных, вопросы переносимости лечения, приведены клинические рекомендации и предупреждения, касающиеся применения данной группы лекарственных препаратов.

anemiaerythropoietinr-HuEporecommendationscomplicationsVero-epoetinанемияэритропоэтинрч-ЭПОрекомендацииосложненияВеро-эпоэтин1. Groopman J.L., Itri L. Chemotherapy induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616–34.Groopman J.L., Itri L. Chemotherapy induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616–34.2. NCCN Clinical Practice Guidelines in Oncology. Cancer- and Treatment-Related Anemia.V.3.2007. www.nccn.orgNCCN Clinical Practice Guidelines in Oncology. Cancer- and Treatment-Related Anemia.V.3.2007. www.nccn.org3. Henry D.H. Supplemental Iron: A Key to optimizing the response of cancer related anemia to rHuEPO. Oncologist 1998;3:275–8.Henry D.H. Supplemental Iron: A Key to optimizing the response of cancer related anemia to rHuEPO. Oncologist 1998;3:275–8.4. Blackwell K., Gascon P., Sigounas G., Jolliffe L. rHuEPO and improved treatment outcomes: potential modes of action. Oncologist 2004;9:41–7.Blackwell K., Gascon P., Sigounas G., Jolliffe L. rHuEPO and improved treatment outcomes: potential modes of action. Oncologist 2004;9:41–7.5. Varlotto J., Stevenson M.A. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005;63(1):25–36.Varlotto J., Stevenson M.A. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005;63(1):25–36.6. Harrison L.B., Chadha M., Hill R.J. et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7(6):492–508.Harrison L.B., Chadha M., Hill R.J. et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7(6):492–508.7. Yasuda Y., Fujita Y., Matsuo T. et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24:1021–9.Yasuda Y., Fujita Y., Matsuo T. et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24:1021–9.8. Leyland-Jones B. Evidence for erythropoietin as a molecular targeting agent. Semin Oncol 2002; 29:145–54.Leyland-Jones B. Evidence for erythropoietin as a molecular targeting agent. Semin Oncol 2002; 29:145–54.9. Mittelman M., Neumann D., Peled A. et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001; 98:5181–6.Mittelman M., Neumann D., Peled A. et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001; 98:5181–6.10. Steensma D.P., Loprinzi C.L. Erythropoietin use in cancer patients: a Matter of life and death? J Clin Oncol 2005; 23(25): 5865–8.Steensma D.P., Loprinzi C.L. Erythropoietin use in cancer patients: a Matter of life and death? J Clin Oncol 2005; 23(25): 5865–8.11. Maiese K., Li F., Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 2005; 293:90–5.Maiese K., Li F., Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 2005; 293:90–5.12. Ekmekcioglu S., Grimm E.A. Cytokines: biology and applications in cancer medicine. In: Holland-Frei Cancer Medicine. 6th ed. BCDecker Inc.; 2003.Ekmekcioglu S., Grimm E.A. Cytokines: biology and applications in cancer medicine. In: Holland-Frei Cancer Medicine. 6th ed. BCDecker Inc.; 2003.13. Ludwig H., Fritz E., Kotzmann H. et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322:1693–9.Ludwig H., Fritz E., Kotzmann H. et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322:1693–9.14. Miller C.B., Jones R.J., Piantadosi S. et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689–92.Miller C.B., Jones R.J., Piantadosi S. et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689–92.15. Cazzola M., Messinger D., Battistel V. et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or nonHodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446–53.Cazzola M., Messinger D., Battistel V. et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or nonHodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446–53.16. Krantz S.B. Erythropoietin. Blood 1991; 77:419–34.Krantz S.B. Erythropoietin. Blood 1991; 77:419–34.17. Littlewood T.J., Bajetta E., Nortier J.W. et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–74.Littlewood T.J., Bajetta E., Nortier J.W. et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–74.18. Seidenfeld J., Piper M., Flamm C. et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204–14.Seidenfeld J., Piper M., Flamm C. et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204–14.19. Vansteenkiste J., Pirker R., Massuti B. et al. Double blind, placebo controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94 (16):1211–20.Vansteenkiste J., Pirker R., Massuti B. et al. Double blind, placebo controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94 (16):1211–20.20. Glaspy J., Bukowski R., Steinberg D. et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol 1997; 15:1218–34.Glaspy J., Bukowski R., Steinberg D. et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol 1997; 15:1218–34.21. Demetri G.D., Kris M., Wade J. et al. Qualityof-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study: Procrit Study Group. J Clin Oncol 1998; 16:3412–25.Demetri G.D., Kris M., Wade J. et al. Qualityof-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study: Procrit Study Group. J Clin Oncol 1998; 16:3412–25.22. Gabrilove J.L., Cleeland C.S., Livingston R.B. et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875–82.Gabrilove J.L., Cleeland C.S., Livingston R.B. et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875–82.23. Desai J., Demetri G.D. Recombinant human erythropoietin in cancer-related anemia: An evidence-based review. Best Pract Res Clin Haematol 2005;18:389–406.Desai J., Demetri G.D. Recombinant human erythropoietin in cancer-related anemia: An evidence-based review. Best Pract Res Clin Haematol 2005;18:389–406.24. Bohlius J., Wilson J., Seidenfeld J. et al. Erythopoietin or darbepoetin for patients with anemia. Cochrane Database System Rev 2006;3:CD003407.Bohlius J., Wilson J., Seidenfeld J. et al. Erythopoietin or darbepoetin for patients with anemia. Cochrane Database System Rev 2006;3:CD003407.25. Ross S.D., Allen I.E., Henry D.H. et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006;28:801–31.Ross S.D., Allen I.E., Henry D.H. et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006;28:801–31.26. Crawford J., Cella D., Cleeland C. et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95(4):888–95.Crawford J., Cella D., Cleeland C. et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95(4):888–95.27. Bohlius J., Langensiepen S., Schwarzer G. et al. Erythropoietin for patients with malignant disease. Cochrane Database System Rev 2004; CD003407.Bohlius J., Langensiepen S., Schwarzer G. et al. Erythropoietin for patients with malignant disease. Cochrane Database System Rev 2004; CD003407.28. Bohlius J., Langensiepen S., Schwarzer G. et al. Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. J Natl Cancer Inst 2000; 97:489–98.Bohlius J., Langensiepen S., Schwarzer G. et al. Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. J Natl Cancer Inst 2000; 97:489–98.29. Leyland-Jones B., Semiglazov V., Pawlicki M. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005; 23:5960–72.Leyland-Jones B., Semiglazov V., Pawlicki M. et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005; 23:5960–72.30. Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–60.Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–60.31. http://www.fda.gov/cder/drug/infopage/RHE/default.htmhttp://www.fda.gov/cder/drug/infopage/RHE/default.htm32. Harrison L.B., Shasha D., White C. et al. Radiotherapy-associated anemia: The scope of the problem. Oncologist 2000;5(Suppl 2):1–7.Harrison L.B., Shasha D., White C. et al. Radiotherapy-associated anemia: The scope of the problem. Oncologist 2000;5(Suppl 2):1–7.33. Henry D.H. Supplemental iron: a key to optimizing the response of cancer related anemia to rHuEPO? Oncologist 1998;3:275–8. 34. Finch C.A. Erythropoiesis, erythropoietin, and iron. Blood 1982;60:1241.Henry D.H. Supplemental iron: a key to optimizing the response of cancer related anemia to rHuEPO? Oncologist 1998;3:275–8. 34. Finch C.A. Erythropoiesis, erythropoietin, and iron. Blood 1982;60:1241.